There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in experimentation is becoming dearer, primarily due to the costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues including concerns for animal welfare.
